Goals

[anonymous]

Patient focused and match the indications with LGS and DS. Where is compliance with this hot mess?

 

[anonymous]

Where is compliance? Swimming. With a dislocated hip. Being a strong independent boss woman, like her shirt says.

 

[anonymous]

Know the payer criteria so you can speak to it = off label patients will help you reach those T1 goals without looking too obvious

 

[anonymous]

Know the payer criteria so you can speak to it = off label patients will help you reach those T1 goals without looking too obvious

CIA!!!!!

 

[anonymous]

Is this company crazy with these absurd “new patient” goals? Does anyone understand rare disease? Please, anyone??

There is only one way to get the patients they say they need and that is off label.

Get ready to hear the whistle blow, folks.

 

[anonymous]

They want to be the #1 company in Epilepsy with an indication for 2 very RARE forms of epilepsy. Only 1 way to get there. This is a whistleblower’s dream place.

 

[anonymous]

They want to be the #1 company in Epilepsy with an indication for 2 very RARE forms of epilepsy. Only 1 way to get there. This is a whistleblower’s dream place.

Let’s see you do something about it tough guy. Suck it! You will never uncover any wrong doing. We’re that good!

 

[anonymous]

Look at Florida y’all. “Broad spectrum” market share and not exactly rare disease DS or lgs indications driving the results, as stated by the MSL teams at the TEM. Shady business

 

[anonymous]

Look at Florida y’all. “Broad spectrum” market share and not exactly rare disease DS or lgs indications driving the results, as stated by the MSL teams at the TEM. Shady business

if it was off label, the payers wouldn’t be approving it, and if they are approving for Refractory patients that need it after a process then what’s the big deal? Doesn’t mean that NAMs are selling off label, means the doctors and staff are fighting for more patients that they want to use it in based on results they have seen.

 

[anonymous]

Leadership goals:
$1 Billion company
#1 in Epilepsy
Pretty lofty for a rare disease drug...be careful folks

 

[anonymous]

Leadership goals:
$1 Billion company
#1 in Epilepsy
Pretty lofty for a rare disease drug...be careful folks

RXs outside the indication are OFF LABEL. Whistle whistle

 

[anonymous]

RXs outside the indication are OFF LABEL. Whistle whistle

No shit dummy. Doctors can try to prescribe for whatever they want. Doesn’t mean things are being promoted off label. Happens with every drug in every disease state. Welcome to the real world.